The National Pharmaceutical Pricing Authority (NPPA) has revised ceiling prices for 138 scheduled drug formulations based on a Wholesale Price Index increase of 0.64956%, effective 1 April 2026. The update spans multiple therapeutic categories including antibiotics, vaccines, oncology, and critical care medicines, requiring manufacturers to comply with revised pricing limits and regulatory provisions under the Drugs (Prices Control) Order, 2013.
The National Pharmaceutical Pricing Authority (NPPA) has revised ceiling prices for 138 scheduled formulations under the Drugs (Prices Control) Order, 2013, based on a Wholesale Price Index increase of 0.64956%.
Effective from 1 April 2026, this update covers a broad range of essential medicines across therapeutic areas such as anti-infectives, vaccines, oncology drugs, cardiovascular treatments, and emergency care products.
Unlike highly limited notifications, this revision applies to a wider basket of essential formulations used in routine and critical care settings, increasing its relevance across healthcare providers and manufacturers.
- Covers 138 scheduled formulations across multiple therapeutic segments
- Includes antibiotics, vaccines, oncology, and critical care medicines
- Manufacturers must ensure prices do not exceed notified ceiling limits
- Downward revision required where MRP exceeds ceiling price
- Form-II submission mandatory within 15 days of price revision
- Retailers must display updated price lists for transparency
This update ensures broader price regulation across essential medicines while maintaining compliance under DPCO, 2013.